Highlights and Quick Summary
- Equity Repurchase (Common, Net) for the quarter ending March 31, 2022 was $3.94 Million (a -110.14% decrease compared to previous quarter)
- Year-over-year quarterly Equity Repurchase (Common, Net) increased by 123.33%
- Annual Equity Repurchase (Common, Net) for 2021 was $18 Thousand (a -73.91% decrease from previous year)
- Annual Equity Repurchase (Common, Net) for 2020 was $69 Thousand (a -38.39% decrease from previous year)
- Annual Equity Repurchase (Common, Net) for 2019 was $112 Thousand (a -182.35% decrease from previous year)
- Twelve month Equity Repurchase (Common, Net) ending March 31, 2022 was $-7.74 Million (a -43105.56% decrease compared to previous quarter)
- Twelve month trailing Equity Repurchase (Common, Net) increased by 3639.61% year-over-year
Trailing Equity Repurchase (Common, Net) for the last four month:
| 31 Mar '22 | 31 Dec '21 | 30 Sep '21 | 30 Jun '21 |
|---|---|---|---|
| $-7.74 Million | $18 Thousand | $18.5 Million | $-207 Thousand |
Visit stockrow.com/ALNA
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical Equity Repurchase (Common, Net) of Allena Pharmaceuticals, Inc.
Most recent Equity Repurchase (Common, Net)of ALNA including historical data for past 10 years.Interactive Chart of Equity Repurchase (Common, Net) of Allena Pharmaceuticals, Inc.
Allena Pharmaceuticals, Inc. Equity Repurchase (Common, Net) for the past 10 Years (both Annual and Quarterly)
(All values are in $ million)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2022 | $3.94 | – | – | – | – |
| 2021 | $-38.88 | $25.43 | $1.77 | $11.7 | $0.02 |
| 2020 | $-20.41 | $6.74 | $13.74 | $0.01 | $0.07 |
| 2019 | $-9.52 | $-0.0 | $9.62 | $0.01 | $0.11 |
| 2018 | $-0.04 | $0.01 | $-0.11 | $0.0 | $-0.14 |
| 2017 | $67.22 | $0.0 | $0.0 | $0.0 | $67.23 |
| 2016 | – | – | – | $0.02 | $0.02 |
| 2015 | – | – | – | – | $0.01 |
Business Profile of Allena Pharmaceuticals, Inc.
Sector: Healthcare
Industry: Biotechnology
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.